Death of the Pharma Salesman
Big Pharma is beginning to explore ways of moving beyond traditional corporate web sites to establish web presences designed to create relationships with their physician and consumer customers. As part of these efforts, some drug companies are experimenting with the e-detailing technologies offered by a growing number of start-ups.Although e-detailing will probably never replace pharmaceutical company sales reps, it may provide large drug companies with a cost-effective way of holding on to profitable niche products that would otherwise fall by the wayside as they focus attention on blockbusters. Perhaps even more significantly, emerging pharmaceutical firms and biotechs may be able to use the Internet to expand their sales and marketing infrastructure capabilities, without incurring huge infrastructure costs, and thus help those smaller companies compete more effectively against larger players.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."